<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00766909</url>
  </required_header>
  <id_info>
    <org_study_id>M-20080060</org_study_id>
    <nct_id>NCT00766909</nct_id>
  </id_info>
  <brief_title>Diabetogenicity of Cyclosporine and Tacrolimus</brief_title>
  <acronym>CSATAC</acronym>
  <official_title>Diabetogenicity of Cyclosporine and Tacrolimus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Aarhus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Aarhus</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Cyclosporine (CsA) and Tacrolimus (Tac) are immunosuppressive agents comprising the
      cornerstone of treatment among organ transplant recipients. Unfortunately diabetes is a known
      complication after transplantation, yet the underlying mechanisms of this type of diabetes
      are still unresolved. A direct comparison of the diabetogenic effects of CsA and Tac, without
      interference of corticosteroid treatment, has not yet been investigated using a
      hyperinsulinemic euglycemic glucose clamp technique, which is the best method for estimating
      insulin sensitivity.

      Randomized, investigator-blinded cross-over studies will be carried out, studying 10 healthy
      subjects and 10 hemodialysis patients. Each participant will receive treatment with CsA, Tac
      and placebo respectively in a random order. The results will be of relevance to the choice
      and monitoring of immunosuppressive regimens in kidney transplant recipients as well as the
      development of better treatment modalities for diabetes.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Background: Post-transplantation diabetes mellitus (PTDM) is a complication of the
      calcineurin inhibitors (CI) cyclosporine (CsA) and Tacrolimus (Tac), but much controversy
      still exists regarding the mechanism leading to this disorder. Several studies using
      intravenous (IVGTT) or oral glucose tolerance tests have shown that CsA and Tac tend to
      reduce insulin release, while corticosteroids increase insulin resistance. Decreased insulin
      secretion may be the result of beta-cell toxicity, apoptosis or inhibition of calcineurin
      signaling cessating insulin gene transcription. Comparing the drug using IVGTT has shown that
      long-term glucose metabolism is not significantly different between the two. Reviewing the
      literature brings forth that some of these data and the observed higher incidence of PTDM in
      Tac-treated recipients are conflicting.

      To or knowledge, comparison of the diabetogenic effects of CsA and Tac, without concomitant
      corticosteroids, has never been investigated using the gold standard to estimate insulin
      sensitivity; a hyperinsulinemic euglycemic glucose clamp (HEGC).

      Hypotheses: CsA and Tac are able to induce diabetes, by exerting acute and chronic effects on
      pancreas beta-cell performance and insulin sensitivity.

      The hypothesized effects will be investigated during following studies:

        1. Acute effect in 10 healthy subjects undergoing HEGC

        2. Chronic effect in 10 pre-transplant uremic patients undergoing HEGC

      Methods: The studies are randomized, double-blinded (Study 1) and investigator blinded (Study
      2) cross-over designs. Each study subject participates in three experimental study days with
      an interval of 4-6 weeks. A HEGC is carried out on the study days, where treatment includes
      CsA, Tac and placebo respectively in random order. Following an overnight fast the healthy
      subject / uremic patient arrives in the research laboratory, where a catheter is implanted in
      each arm for blood sampling and infusion purposes.

      Pulse induction: Glucose 6 mg/kg/min is infused every 10 minutes followed by a 9 minute
      pause. From 30 to 90 min blood is drawn every minute for insulin and every 10th minute for
      glucose measurements.

      First phase insulin secretion: After 120 minutes glucose 0.3 g/kg (maximally 25 g) is infused
      over 2 min and the catheter is flushed with 50 ml of isotonic saline. Insulin, glucose and
      c-peptide are measured with a few minutes intervals.

      Insulin infusion/HEGC: 1.0 mU/kg/min insulin infusion is initiated at the 165th minute and
      blood glucose levels are kept at 5.0 mmol/L, using variable infusion of a 20% glucose
      dilution throughout the following 120 minutes. The final 30 min of the clamp is considered
      the hyperinsulinaemic steady state period. Aside from glucose, insulin and other
      endocrinological parameters, measurements of drug concentration and CaN will also be
      performed.

      Perspectives: The studies are expected to give valuable insight into the diabetogenic effects
      of CI, and to show whether or not CsA and Tac are comparable in their Diabetogenicity. The
      results will be of relevance to the choice and monitoring of immunosuppressive regimens in
      kidney transplant recipients as well as the development of better treatment modalities for
      diabetes.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2008</start_date>
  <completion_date type="Actual">November 2011</completion_date>
  <primary_completion_date type="Actual">June 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Insulin Sensitivity</measure>
    <time_frame>Serial measurements during 120 minute Hyperinsulinemic euglycemic clamp investigation. Performed 3 times on 3 individual days within 4 months after inclusion</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>insulin secretion</measure>
    <time_frame>Serial measurements during IVGTT. Performed 3 times on 3 individual days within 4 months after inclusion.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum free fatty acids</measure>
    <time_frame>Serial measurements during 5-hour infusions of CsA, Tac or saline. Performed 3 times on 3 individual days within 4 months after inclusion.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum C-peptide</measure>
    <time_frame>erial measurements during 5-hour infusions of CsA, Tac or saline. Performed 3 times on 3 individual days within 4 months after inclusion.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood cyclosporine</measure>
    <time_frame>erial measurements during 5-hour infusions of CsA, Tac or saline. Performed 3 times on 3 individual days within 4 months after inclusion.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>blood tacrolimus</measure>
    <time_frame>Serial measurements during 5-hour infusions of CsA, Tac or saline. Performed 3 times on 3 individual days within 4 months after inclusion.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>respiratory gas exchange, substrate metabolism</measure>
    <time_frame>Indirect calorimetry performed 3 times on 3 individual days within 4 months after inclusion.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pulsatile Insulin secretion</measure>
    <time_frame>erial measurements during glucose entrainment. Performed 3 times on 3 individual days within 4 months after inclusion.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma Glucose</measure>
    <time_frame>erial measurements during 5-hour infusions of CsA, Tac or saline. Performed 3 times on 3 individual days within 4 months after inclusion.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>plasma glucagon</measure>
    <time_frame>erial measurements during 5-hour infusions of CsA, Tac or saline. Performed 3 times on 3 individual days within 4 months after inclusion.</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Complications of Transplanted Organs and Tissue</condition>
  <condition>Diabetes Mellitus Nos New Onset</condition>
  <arm_group>
    <arm_group_label>CsA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Cyclosporine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Tac</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tacrolimus</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo/saline</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
    <description>For Healthy volunteers (study 1) and Dialysis patients (study 2): Single intravenous infusion of 0.155 mg/kg over a maximum duration of 5 hours.
For Dialysis Patients (study 2): Oral intake of 4 mg/kg 2 times daily for 8-11 days.</description>
    <arm_group_label>CsA</arm_group_label>
    <other_name>Sandimmun</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tacrolimus</intervention_name>
    <description>For Healthy volunteers (study 1) and Dialysis patients (study 2): Single intravenous infusion of 0.0012 mg/kg over a maximum duration of 5 hours.
For Dialysis Patients (study 2): Oral intake of 0.1 mg/kg 2 times daily for 8-11 days.</description>
    <arm_group_label>Tac</arm_group_label>
    <other_name>Prograf</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Capsules and isotonic saline</intervention_name>
    <description>For Healthy volunteers (study 1) and Dialysis patients (study 2): Single intravenous infusion of 0.06 ml/kg isotonic saline over a maximum duration of 5 hours.
For Dialysis patients (study 2): Placebo capsules 2 times daily for 8-11 days.</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Saline</other_name>
    <other_name>NaCl</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

        Healthy volunteers (Study 1):

          1. Men.

          2. Age between 18 years and 50 years. Upper limit can be +2 years if approved by main
             investigator.

          3. Normal OGTT (0 and 120 min test).

          4. Body mass index (BMI) 20 - 30 kg/m2. Allowed variations are 5% from the upper and
             lower limit.

          5. Normal serum creatinine and ionisized calcium. Allowed variations are 20% from the
             upper and lower limit of the normal value for creatinine and 5% for calcium.

          6. Normal urine stix

          7. Written consent to participate.

        Hemodialysis Patients (study 2):

          1. Age between 18 years and 70 years. Upper limit can be +2 years if approved by main
             investigator.

          2. BMI &lt; 30 kg/m2. Allowed variations are 5% over the upper limit.

          3. On the waiting-list for a kidney transplant.

          4. Haemodialysis candidate.

          5. Anti-conceptive treatment (contraceptive pill/intrauterine device/patch/ring/
             implant/injectable contraceptive) if the patient is a fertile woman.

          6. Written consent to participate. -

        Exclusion Criteria:

        Healthy volunteers (Study 1):

          1. Anaemia with haemoglobin levels &lt; 7 mmol/L

          2. Participation in any other clinical trial.

          3. Subjects who cannot adhere to test conditions.

          4. Anamnesis of clinically significant disease, such as:

               -  liver disease

               -  kidney disease,

               -  neurological disease

               -  gastrointestinal disease

               -  haematological disease

               -  endocrine disease

               -  lung disease

               -  cardiac disease

          5. Drug or alcohol abuse, which would render the subject unfit according to the main
             investigator.

          6. Blood donation 1 month prior to the study day

          7. Patients with established allergy against CI or other medical products, which might
             pose a risk if they participated in this study.

          8. Use of prescription drugs within one month prior to the study days, unless they are
             clinically insignificant according to the main investigator.

          9. Smoking 8 hours prior to the study day

         10. Vigorous exercise 30 minutes prior to the study day.

        Hemodialysis Patients (study 2):

          1. Peritoneal dialysis.

          2. Anaemia with haemoglobin levels &lt; 6 mmol/L.

          3. Participation in any other clinical trial.

          4. Treatment with corticosteroids, CsA or Tac.

          5. Patients who cannot adhere to test conditions.

          6. Patients with established allergy against CI or other medical product, which might
             pose a risk if they participated in this study.

          7. Drug or alcohol abuse, which would render the subject unfit according to the main
             investigator.

          8. Anamnesis of current diabetes and/or intake of anti-diabetic medication.

          9. Malignancy.

         10. Uncontrolled infection.

         11. Uncontrolled hypertension.

         12. Smoking 8 hours prior to the study day.

         13. Vigorous exercise 30 minutes prior to the study day
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lara Aygen Ã˜zbay, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Aarhus University Hospital Skejby</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Department of Nephrology, Aarhus University Hospital, Skejby</name>
      <address>
        <city>Aarhus</city>
        <state>Jutland</state>
        <zip>8200</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>November 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 3, 2008</study_first_submitted>
  <study_first_submitted_qc>October 3, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 6, 2008</study_first_posted>
  <last_update_submitted>November 7, 2011</last_update_submitted>
  <last_update_submitted_qc>November 7, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 8, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Insulin pulsatility</keyword>
  <keyword>Insulin secretion</keyword>
  <keyword>Insulin sensitivity</keyword>
  <keyword>Calcineurin inhibitor</keyword>
  <keyword>Cyclosporine</keyword>
  <keyword>Tacrolimus</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tacrolimus</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

